Meitheal Pharmaceuticals has Mitomycin for Injection, USP Now Available

Share Facebook icon Twitter icon Linkedin icon

Meitheal Pharmaceuticals (Meitheal) is pleased to announce that we have launched Mitomycin for Injection, USP, in 5 mg per vial in a single-dose vial, 20 mg per vial in a single-dose vial, and 40 mg per vial in a single-dose vial.

Meitheal will offer Mitomycin for Injection, USP in a pack of 1 vial for all 3 presentations.



Mitomycin for Injection is not recommended as single-agent, primary therapy. It has been shown to be useful in the therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. It is not recommended to replace appropriate surgery and/or radiotherapy. For full prescribing and safety information, please click on the following links (5mg & 20mg PI and 40 mg PI).


Learn more about Mitomycin for Injection, USP

This Website Uses Cookies

This website uses cookies to help give you the best experience when you visit. By clicking “Accept Cookies,” you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and help us make improvements to our site. You can read more about our use of cookies in our Privacy Policy.

Manage Consent Preferences

Always Active

Necessary cookies enable core functionality such as security and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

These cookies are set to provide quantitative measures of website visitors. Information collected with these cookies is used in operations to measure website performance. With the usage of these cookies we are able to count visits and traffic sources to improve our site. The data is collected in a way that does not directly identify anyone.
Accept all cookies Confirm my choices